| _ | In | re | App | lication | of | |
|---|----|----|-----|----------|----|--|
| | | | | | | |

Harvey A. Schwertner et al Filed

Application Number

10/016.826

November 9, 2001

Docket Number (Optional)

AFD 490

BILIRUBIN TESTS AS RISK PREDICTORS FOR CANCER MORTALITY, RHEUMATOID ARTHRITIS, GILBERT'S SYNDROME AND ALL-CAUSE

MORTALITY

Group Art Unit Examiner

1743

Maureen Wallenhorst

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

One month (37 CFR 1.17(a)(1))

110.00

Two months (37 CFR 1.17(a)(2))

410.00

Three months (37 CFR 1.17(a)(3))

930.00

Four months (37 CFR 1.17(a)(4))

1,450.00

Five months (37 CFR 1.17(a)(5))

- 1.970.00
- Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ ______ .
- A check in the amount of the fee is enclosed.
- Payment by credit card. Form PTO-2038 is attached.
- The Commissioner has already been authorized to charge fees in this application to a Deposit Account.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number AF 01-0465. I have enclosed a duplicate copy of this sheet.

I am the

applicant/inventor

assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

attorney or agent of record.

attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a).

Fredric L. Sinder, Reg. No. 28,475

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required. See below.

Total of form(s) are submitted. 00000045 010465 11/05/2003 JADD01